H3 Biomedicine

h3biomedicine.com

H3 Biomedicine is a privately held biopharmaceutical company focused on the discovery and early development of novel, targeted anti-cancer compounds for the unmet needs of genetically defined patient populations. H3 has leveraged its integrated expertise in genomics, tumor biology, bioinformatics and innovative synthetic organic chemistry to create an integrated drug development ecosystem to deliver patient-based, genomics-driven, small molecule drugs. In less than three years, H3 has developed four discovery platforms, which have produced two drug candidates for which the company expects to file investigational new drug (IND) applications in late 2015.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

DISPERSOL TECHNOLOGIES ANNOUNCES COLLABORATION WITH AJAX THERAPEUTICS TO DEVELOP ENHANCED KINETISOL DRUG FORMULATIONS

DisperSol Technologies | December 18, 2021

news image

DisperSol Technologies LLC announced that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies. “Ajax is taking an innovative approach to developing a pipeline of selectively targeted small molecules and we look forward to applying our proprietary KinetiSol technology to help enha...

Read More

REASONS FOR HOPE: THE DRUGS, TESTS AND TACTICS THAT MAY CONQUER CORONAVIRUS

Times Now | April 14, 2020

news image

With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus. While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinic...

Read More

Business Insights

EYEPOINT PHARMACEUTICALS ANNOUNCED A DEBT REFINANCING WITH SILICON VALLEY BANK FOR $45 MILLION IN CREDIT FACILITIES

EyePoint Pharmaceuticals, Inc. | March 10, 2022

news image

A pharmaceutical company, EyePoint Pharmaceuticals, Inc.dedicated to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it has entered into a loan agreement with Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC for senior secured credit facilities for $45 million (CRG). A $30 million term loan facility and an asset-based revolving credit facility of up to $15 million will be used to replac...

Read More

Pharma Tech

EUROPEAN MEDICINES AGENCY ACCEPTS ASTELLAS' MARKETING AUTHORIZATION APPLICATION FOR FEZOLINETANT

Astellas Pharma Inc. | September 30, 2022

news image

Astellas Pharma Inc. announced the European Medicines Agency has accepted for regulatory review the company's marketing authorization application for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.1,2 "More than half of women 40 to 64 years of age ex...

Read More
news image

Research

DISPERSOL TECHNOLOGIES ANNOUNCES COLLABORATION WITH AJAX THERAPEUTICS TO DEVELOP ENHANCED KINETISOL DRUG FORMULATIONS

DisperSol Technologies | December 18, 2021

DisperSol Technologies LLC announced that it is has entered into a research collaboration with Ajax Therapeutics, Inc. to apply its KinetiSol technology to enhance the bioavailability of an Ajax drug candidate in development for the treatment of hematologic malignancies. “Ajax is taking an innovative approach to developing a pipeline of selectively targeted small molecules and we look forward to applying our proprietary KinetiSol technology to help enha...

Read More
news image

REASONS FOR HOPE: THE DRUGS, TESTS AND TACTICS THAT MAY CONQUER CORONAVIRUS

Times Now | April 14, 2020

With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus. While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinic...

Read More
news image

Business Insights

EYEPOINT PHARMACEUTICALS ANNOUNCED A DEBT REFINANCING WITH SILICON VALLEY BANK FOR $45 MILLION IN CREDIT FACILITIES

EyePoint Pharmaceuticals, Inc. | March 10, 2022

A pharmaceutical company, EyePoint Pharmaceuticals, Inc.dedicated to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it has entered into a loan agreement with Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC for senior secured credit facilities for $45 million (CRG). A $30 million term loan facility and an asset-based revolving credit facility of up to $15 million will be used to replac...

Read More
news image

Pharma Tech

EUROPEAN MEDICINES AGENCY ACCEPTS ASTELLAS' MARKETING AUTHORIZATION APPLICATION FOR FEZOLINETANT

Astellas Pharma Inc. | September 30, 2022

Astellas Pharma Inc. announced the European Medicines Agency has accepted for regulatory review the company's marketing authorization application for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.1,2 "More than half of women 40 to 64 years of age ex...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us